Dr. Anil Diwan is President & Exec. Chairman of NanoViricides, Inc, a public company (NYSE-Amer.: NNVC; co-founded 2005). He has over 35 years of entrepreneurial experience in biotech/pharma fields. He co-invented the bio-mimetic drug delivery platform, nanoviricides™ polymeric micelles, enabling site-specific targeting, multi-point attack, & encapsulation. Orally available, host-mimetic, direct-acting, nanoviricide drug NV-387 has successfully completed Phase I in healthy subjects and is being developed into Phase II. NV-387 has shown strong pre-clinical efficacy in RSV, Influenza, COVID as well as Orthopoxvirus in lethal virus challenge animal models, attesting to its broad spectrum, reminiscent of antibiotics. Nanoviricides define a new paradigm “Re-Infection Inhibition”, going beyond antibodies and small chemicals. The platform further enables cures of viral infections by encapsulating orthogonal APIs such as Remdesivir, Ribavirin, Cidofovir, etc. Dr. Diwan was instrumental in designing and establishing the NanoViricides campus in Shelton that comprises R&D to Clinical Trial Drug Product Manufacturing facility of our nanomedicines. Dr. Diwan has published several papers in nanomedicines, virology, and neuroscience, cell therapy fields. Dr. Diwan holds a PhD, (Bio)Chemical Engineering, Rice University and a BTech, Chemical Engineering, Indian Institute of Technology, Bombay (IITB).